Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and... Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. Mehr anzeigen
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2 | -11.0497237569 | 1.81 | 1.93 | 1.62 | 109218 | 1.73767334 | CS |
| 4 | -0.14 | -8 | 1.75 | 2.52 | 1.44 | 303103 | 1.80613935 | CS |
| 12 | -1.67 | -50.9146341463 | 3.28 | 4.85 | 1.41 | 1134259 | 1.97029437 | CS |
| 26 | -4.55008 | -73.8639757925 | 6.16008 | 10 | 1.41 | 769051 | 2.78829477 | CS |
| 52 | -9.59 | -85.625 | 11.2 | 18.7192 | 1.41 | 420736 | 3.77917535 | CS |
| 156 | -774.55 | -99.7925685426 | 776.16 | 1649.4016 | 1.41 | 1909907 | 552.40216519 | CS |
| 260 | -15324.47 | -99.9894950307 | 15326.08 | 39916.8 | 1.41 | 2282301 | 2544.98425268 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
